Merck makes big push into Covid-19 arena with three new deals, including one with Miami biotech

Merck& Co. expanded its efforts to prevent and treat Covid-19 in a big way Tuesday with three deals aimed at developing both vaccines and therapies for the new strain of the coronavirus. In one deal, Merck (NYSE: MRK) said it has reached an agreement to acquire Themis Bioscience, an Austrian vaccine developer. Merck also announced a Covid-19 vaccine collaboration with IAVI, a nonprofit organization, and a partnership with Miami-based Ridgeback Biotherapeutics to develop Covid-19 therapies. Dr.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news